COMMUNIQUÉS West-GlobeNewswire

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
01/05/2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an [...]
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
01/05/2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with [...]
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
01/05/2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $ [...]
Coloplast A/S Revised guidance for FY 2024/25
01/05/2025
Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic [...]
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
01/05/2025
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful [...]
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
01/05/2025
Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical- [...]
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
01/05/2025
The Canadian Dermatology Association highlights sun safety in the True North, with a focus on shade, prevention, and early detection. OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns [...]
Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil
01/05/2025
L’Association canadienne de dermatologie insiste sur l’importance de se protéger du soleil dans le cadre de sa campagne Prudence sous le soleil du Nord, en mettant l’accent sur l’ombrage, la prévention et la détection [...]
PhenQ Reviews: Can This Thermogenic Fat Burner Help You Burn Fat? A Detailed Report By Riti Health Experts
01/05/2025
Read the latest PhenQ review from Riti Health experts. Find out if this popular thermogenic fat burner can boost energy and help you burn stubborn fat. Dover, Delaware, May 01, 2025 (GLOBE NEWSWIRE) -- Fat-burning [...]
AB Science will publish its 2024 annual financial report on May 9, 2025
01/05/2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1 st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of [...]
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
01/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1 er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la [...]
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
01/05/2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
01/05/2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
01/05/2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio , a biopharmaceutical company [...]
Roquette Completes the Acquisition of IFF Pharma Solutions
01/05/2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the [...]
Roquette finalise l’acquisition d’IFF Pharma Solutions
01/05/2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la [...]
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
01/05/2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
01/05/2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 [...]
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
01/05/2025
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today [...]

Pages